Lifestyle economist Christopher Snowdon joins Michael Simmons to explore how weight-loss drugs like Ozempic could reshape health, policy and the economy. From the WHO’s call for mass production to flawed obesity cost estimates, failing ‘nanny state’ interventions and the future of food companies, Snowden argues that these drugs are a genuine game-changer — and warns that much of current public health thinking is fast becoming obsolete.

Become a Spectator subscriber today to access this podcast without adverts. Go to spectator.co.uk/adfree to find out more.

For more Spectator podcasts, go to spectator.co.uk/podcasts

Contact us: podcast@spectator.co.uk

Hosted on Acast. See acast.com/privacy for more information.